Fennec Pharmaceuticals Inc. (FENC) EPS Estimated At $-0.15

March 15, 2018 - By Winifred Garcia

 Fennec Pharmaceuticals Inc. (FENC) EPS Estimated At $ 0.15

Analysts expect Fennec Pharmaceuticals Inc. (NASDAQ:FENC) to report $-0.15 EPS on March, 29.They anticipate $0.07 EPS change or 87.50 % from last quarter’s $-0.08 EPS. After having $-0.15 EPS previously, Fennec Pharmaceuticals Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.59% or $0.06 during the last trading session, reaching $9.43. About 68,977 shares traded or 190.92% up from the average. Fennec Pharmaceuticals Inc. (NASDAQ:FENC) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $173.62 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

More notable recent Fennec Pharmaceuticals Inc. (NASDAQ:FENC) news were published by: Marketwired.com which released: “Essetifin Announces Acquisition of Additional Shares of Fennec Pharmaceuticals …” on May 17, 2016, also Seekingalpha.com with their article: “Otonomy’s $525 Million Dive Is Fennec’s Good Fortune” published on November 02, 2017, Globenewswire.com published: “Fennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market” on September 11, 2017. More interesting news about Fennec Pharmaceuticals Inc. (NASDAQ:FENC) were released by: Globenewswire.com and their article: “Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK …” published on October 16, 2017 as well as Seekingalpha.com‘s news article titled: “Fennec Pharma’s lead product candidate shows treatment benefit in late-stage …” with publication date: September 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.